


Avocado Research Chemicals Limited

Annual report and financial statements for the year ended 31. December 2022

Company registration number: 02682211



AVOCADO RESEARCH CHEMICALS LIMITED

ANNUAL REPORT AND FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2022

Contents	Page
Officers and Professional Advisers	1
Strategic Report for the Year Ended 31 December 2022	2 to 5
Directors' Report for the Year Ended 31 December 2022	6 to 8
Independent Auditors' Report to the Members of Avocado Research Chemicals Limited	9 to 11
Financial Statements for the Year Ended 31 December 2022:	
• Profit and Loss Account	12
• Balance Sheet	13
• Statement of Changes in Equity	14
Notes to the Financial Statements for the Year Ended 31 December 2022	15 to 34

AVOCADO RESEARCH CHEMICALS LIMITED

OFFICERS AND PROFESSIONAL ADVISERS

Directors

A Smith
D Norman
E Cameron
S Ahmed
N Burbidge

Company Secretary

Oakwood Company Secretary Limited
R Gregg

Registered office

3rd Floor
1 Ashley Road
Altrincham
Cheshire
WA14 2DT

Bankers

Barclays Bank
1 Churchill Place
London
E14 5HP

Solicitors

Addleshaw Goddard
1 St Peter's Square
Manchester
M2 3DE

Independent auditors

PricewaterhouseCoopers LLP
Chartered Accountants and Statutory Auditors
1 Hardman Square
Manchester
M3 3EB

AVOCADO RESEARCH CHEMICALS LIMITED

STRATEGIC REPORT FOR THE YEAR ENDED 31 DECEMBER 2022

The directors present their Strategic Report on the company for the year ended 31 December 2022.

Review of the business and future developments

The directors are satisfied with the performance in the year as the business performed consistently, with good turnover growth. Turnover has grown to £25,791,000 (2021: £24,288,000). The directors expect to see operational growth in 2023.

The company will continue to operate within its existing markets for the foreseeable future.

Total operating margins unchanged in relation to sales to 0% (2021: -1%). Margins have remained broadly consistent with the prior period numbers.

The company continues to invest in research and development. This is expected to maintain and expand the company's firm positioning in the market. Research and development expenditure during the year was £180,000 (2021: £177,000).

Key performance indicators (KPI's)

The directors believe that the key performance indicators ('KPIs') are revenue growth and profitability.

Total revenue has increased from £24,288,000 in 2021 to £25,791,000 in 2022, as a result of the business concentrating on core sourcing & manufacturing capabilities which helped neutralise against strong competition. This enabled the business to maintain steady growth overall for the period.

The Loss for the financial year was £(124,000) (2021: Loss £14,000) mainly driven by increased utility, freight and payroll costs in a highly inflationary market.

Cost of sales has increased at a proportionally lower rate to revenue resulting in an increase in gross profit margins to 19% (2021: 16%).

Employee numbers have increased to 140 (2021: 125) in the year.

Net assets at 31 December 2022 were £17,740,000 (2021: £17,657,000).

Statement by the directors of their statutory duties in accordance with Section 172(1) of the Companies Act 2006

The directors of the company have acted in accordance with a set of general duties. These duties are detailed in section 172 of the Companies Act 2006 which is summarised as follows:

'Each director of the company has acted in the way they consider, in good faith, would be most likely to promote the success of the company for the benefit of its members as a whole, and in doing so have regard (amongst other matters) to:

- the likely consequences of any decision in the long term,
- the interests of the company's employees,
- the need to foster the company's business relationships with suppliers, customers and others,
- the impact of the company's operations on the community and the environment,
- the desirability of the company maintaining a reputation for high standards of business conduct,
- the need to act fairly as between members of the company.'

As part of the director induction process, a director is briefed on their duties and they can access professional advice on these from the company secretary. The following paragraphs summarise how the directors fulfil their duties.

AVOCADO RESEARCH CHEMICALS LIMITED

STRATEGIC REPORT FOR THE YEAR ENDED 31 DECEMBER 2022

Risk management

As we continue to grow our business our risk environment also becomes more complex. It is therefore vital that we effectively identify, evaluate, manage and mitigate the risks we face and that we continue to evolve our approach to risk management.

For details of our principal risks and uncertainties and how we manage those risks, please refer to the principal risks section within the Strategic Report.

Business relationships

Our mission is to enable our customers to make the world healthier, cleaner and safer and as a result of this mission we have created a culture where our customers come first. Part of our business strategy is to continue to strengthen our company to be the partner customers rely on to help them achieve their goals. This is achieved through delivering a unique value proposition to our customers.

As a company we place great importance on building and maintaining strong relationships with our suppliers. The company is committed to meeting payment terms agreed with suppliers and we seek to resolve queries in an efficient and professional manner.

Our colleagues

None of our accomplishments would be possible without our team. Inspired by our mission, and grounded by our 4i values (integrity, intensity, innovation and involvement) this motivates our team to bring their best every day. It also helps us to attract and retain talent which is critical to our future. We invest in our colleagues through numerous development programs that enrich their individual experiences, stress the importance of teams and build skills that set them up for success.

Community and environment

Our mission is to enable our customers to make the world healthier, cleaner and safer. One way that we fulfil our Mission is by being a socially responsible community partner. Our giving strategy includes educational programs, colleague donations and volunteering.

Our signature STEM education programs connect students and colleagues through hands on and team based activities that highlight our technologies, make connections to careers in STEM and demonstrate how our company impacts the world.

To promote the generous spirit of our colleagues, our Charitable Giving Program provides a platform that allows them to contribute to causes that they feel passionately about. Through the program, employees can make direct donations to a charity of their choice, create a fundraiser - gathering greater support for a cause, or contribute to support a disaster relief campaign. Through our Employee Matching Gift program, we help employees make an even bigger impact by matching their contribution to eligible charities by 50%.

We feel it is important to support our community, throughout the year we encourage employees to take part in volunteering and charity events where our employees, together with our charity partners, take part in hands on volunteering.

The company is a part of Thermo Fisher Scientific Inc.'s global strategy to reduce our carbon footprint by 30% by 2030. As part of this global initiative we are committed to reviewing and reducing greenhouse gas emissions.

AVOCADO RESEARCH CHEMICALS LIMITED

STRATEGIC REPORT FOR THE YEAR ENDED 31 DECEMBER 2022

Principal risks and uncertainties

The management of the business is subject to a number of risks including commercial risk, price risk, credit risk, currency risk and interest rate cash flow risk. The mitigation of these risks has been outlined below.

Commercial risk

The company continues to improve its services in order to maintain and develop its market place penetration as evidenced by the investment in research and development of new products.

Financial risk management

The company's operations expose it to a variety of financial risks that include the effects of changes in price risk, credit risk, currency risk and interest rate cash flow risk. The company has in place a risk management programme that seeks to limit the adverse effects on the financial performance of the company by monitoring levels of debt finance and the related finance costs.

In order to ensure stability of cash outflows and hence manage interest rate risk, the company is supported by fellow group operations. The company does not use derivative financial instruments to manage interest rate costs and as such, no hedge accounting is applied.

Given the size of the company, the directors have not delegated the responsibility of monitoring financial risk management to a sub-committee of the board. The policies set by the board of directors are implemented by the company's finance department. The department has a policy and procedures manual that sets out specific guidelines to manage interest rate risk, credit risk and circumstances where it would be appropriate to use financial instruments to manage these.

Price risk

The company is exposed to commodity price risk as a result of its operations. However, given the size of the company's operations, the costs of managing exposure to commodity price risk exceed any potential benefits. The directors will revisit the appropriateness of this policy should the company's operations change in size or nature.

Credit risk

The company has implemented policies that require appropriate credit checks on potential customers before sales are made. The amount of exposure to any individual counterparty is subject to a limit, which is continually reviewed by the senior management team.

Liquidity risk

The company's debt profile is largely short-term debt finance with other group companies that is designed to ensure the company has sufficient available funds for operations and planned expansions.

Currency risk

The company is exposed to currency risk as a result of its operations. However, given the size of the company's operations, the cost of managing the exposure to currency risk through the use of derivative financial instruments exceeds any potential benefits, and as such no hedge accounting is applied. The company operates foreign currency bank accounts in order to offset foreign currency receipts and payments.

Interest rate cash flow risk

The company has interest bearing assets. Interest bearing assets include cash balances and on group loans, all of which earn interest at fixed and variable rates. The directors will revisit the appropriateness of this policy should the company's operations change in size or nature. Interest payable is on bank loans and overdrafts and therefore management of cash flows is taken account of as part of the group's financing activity.

AVOCADO RESEARCH CHEMICALS LIMITED

STRATEGIC REPORT FOR THE YEAR ENDED 31 DECEMBER 2022

DocuSigned by:

Euan Cameron

231F18E0E41648D...

On behalf of the board

E Cameron

Director

26 July 2023

AVOCADO RESEARCH CHEMICALS LIMITED

DIRECTORS' REPORT FOR THE YEAR ENDED 31 DECEMBER 2022

The directors present their report and the audited financial statements of the company for the year ended 31 December 2022.

Outlook

The company mobilized to support the global novel strain of coronavirus (COVID-19) response with products and services that help analyse, diagnose and protect from the virus. Our ability to manufacture/sell products is highly dependent on our ability to maintain the safety and health of our factory employees which we are acting to mitigate in accordance with government guidelines. The company saw an increase in revenue due to the sales of products addressing the diagnosis and treatment of COVID-19 and while these positive impacts are expected to continue into 2022, the duration and extent of future revenues from such sales are uncertain and dependent on customer demand. The company believes its long term prospects remain excellent given the attractive markets served, its industry leading position and proven growth strategy.

Future developments

Future developments are deemed to be of strategic importance to the company and as such have been outlined within the strategic report.

Dividends

The directors do not recommend the payment of a dividend in 2022 (2021: £7,500,000).

Financial risk management

Disclosures relating to these areas are included in the strategic report.

Directors

The directors who held office during the year and up to the date of signing the financial statements are given below:

A Smith
D Norman
E Cameron
S Ahmed
N Burbidge

Third party indemnity provision

The company has made qualifying third party indemnity provisions for the benefit of its directors (which extend to the performance of any duties as a director of any associated company) and these were in force during the year and they remain in force at the date of this report.

Research and development

The company encourages research and development investment. Research and development programmes are managed to obtain a balance between improvements to existing products and development of new products. Research and development costs during the year were £179,935,000 (2021: £177,000).

AVOCADO RESEARCH CHEMICALS LIMITED

DIRECTORS' REPORT FOR THE YEAR ENDED 31 DECEMBER 2022

Statement of directors' responsibilities in respect of the financial statements

The directors are responsible for preparing the Annual Report and the financial statements in accordance with applicable law and regulation.

Company law requires the directors to prepare financial statements for each financial year. Under that law the directors have prepared the financial statements in accordance with United Kingdom Generally Accepted Accounting Practice (United Kingdom Accounting Standards, comprising FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland", and applicable law).

Under company law the directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the company and of the profit or loss of the company for that period. In preparing the financial statements, the directors are required to:

- select suitable accounting policies and then apply them consistently;
- state whether applicable United Kingdom Accounting Standards, comprising FRS 102, have been followed, subject to any material departures disclosed and explained in the financial statements;
- make judgements and accounting estimates that are reasonable and prudent; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the company will continue in business.

The directors are also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

The directors are responsible for keeping adequate accounting records that are sufficient to show and explain the company's transactions and disclose with reasonable accuracy at any time the financial position of the company and enable them to ensure that the financial statements comply with the Companies Act 2006.

Director's confirmations

In the case of each director in office at the date the directors' report is approved:

- So far as the director is aware, there is no relevant audit information of which the company's auditors are unaware; and
- they have taken all the steps that they ought to have taken as a director in order to make themselves aware of any relevant audit information and to establish that the company's auditors are aware of that information.

This confirmation is given and should be interpreted in accordance with the provisions of Section 418 of the Companies Act 2006.

Going Concern

The company meets its day-to-day working capital requirements through its bank facilities. The current economic conditions continue to create uncertainty over (a) the level of demand for the company's products; and (b) the availability of bank finance for the foreseeable future.

The company's forecasts and predictions, taking account of reasonably possible changes in trading performance, show that the directors have a reasonable expectation that the company has access to adequate resources to continue in operational existence for the foreseeable future. The company therefore continues to adopt the going concern basis in preparing its financial statements.

AVOCADO RESEARCH CHEMICALS LIMITED

DIRECTORS' REPORT FOR THE YEAR ENDED 31 DECEMBER 2022

As a participant in the cash sweep arrangement, a letter of support has been obtained from Thermo Fisher Inc, who have confirmed they will continue to support the company and provide any further intercompany financing, if required, for a period of 12 months from the date of approval of the financial statements.

After making enquiries, the directors have a reasonable expectation that the company has adequate resources to continue in operational existence for a period of at least 12 months from the date of approving these financial statements. The company therefore, continues to adopt the going concern basis in preparing its financial statements.

Independent Auditors

The auditors, PricewaterhouseCoopers LLP, have indicated their willingness to continue in office and a resolution concerning their reappointment will be proposed at the annual general meeting.

Strategic Report

The company has chosen in accordance with Companies Act 2006, s.414C(11) to set out in the company's strategic report information required by Large and Medium-sized Companies and Groups (Accounts and Reports) Regulations 2008, Sch. 7 to be contained in the directors' report.

On behalf of the board


E Cameron
Director

26 July 2023

Independent auditors' report to the members of Avocado Research Chemicals Limited

Report on the audit of the financial statements

Opinion

In our opinion, Avocado Research Chemicals Limited's financial statements:

- give a true and fair view of the state of the company's affairs as at 31 December 2022 and of its loss for the year then ended;
- have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice (United Kingdom Accounting Standards, including FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland", and applicable law); and
- have been prepared in accordance with the requirements of the Companies Act 2006.

We have audited the financial statements, included within the Annual report and financial statements (the "Annual Report"), which comprise: the Balance Sheet as at 31 December 2022; the Profit and Loss Account and the Statement of Changes in Equity for the year then ended; and the notes to the financial statements, which include a description of the significant accounting policies.

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) ("ISAs (UK)") and applicable law. Our responsibilities under ISAs (UK) are further described in the Auditors' responsibilities for the audit of the financial statements section of our report. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Independence

We remained independent of the company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, which includes the FRC's Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements.

Conclusions relating to going concern

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

In auditing the financial statements, we have concluded that the directors' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

However, because not all future events or conditions can be predicted, this conclusion is not a guarantee as to the company's ability to continue as a going concern.

Our responsibilities and the responsibilities of the directors with respect to going concern are described in the relevant sections of this report.

Reporting on other information

The other information comprises all of the information in the Annual Report other than the financial statements and our auditors' report thereon. The directors are responsible for the other information. Our opinion on the financial statements does not cover the other information and, accordingly, we do not express an audit opinion or, except to the extent otherwise explicitly stated in this report, any form of assurance thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit, or otherwise appears to be materially misstated. If we identify an apparent material inconsistency or material misstatement, we are required to perform procedures to conclude whether there is a material misstatement of the financial statements or a material misstatement of the other information. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report based on these responsibilities.

With respect to the Strategic report and Directors' Report, we also considered whether the disclosures required by the UK Companies Act 2006 have been included.

Based on our work undertaken in the course of the audit, the Companies Act 2006 requires us also to report certain opinions and matters as described below.

Strategic report and Directors' Report

In our opinion, based on the work undertaken in the course of the audit, the information given in the Strategic report and Directors' Report for the year ended 31 December 2022 is consistent with the financial statements and has been prepared in accordance with applicable legal requirements.

In light of the knowledge and understanding of the company and its environment obtained in the course of the audit, we did not identify any material misstatements in the Strategic report and Directors' Report.

Responsibilities for the financial statements and the audit

Responsibilities of the directors for the financial statements

As explained more fully in the Statement of directors' responsibilities in respect of the financial statements, the directors are responsible for the preparation of the financial statements in accordance with the applicable framework and for being satisfied that they give a true and fair view. The directors are also responsible for such internal control as they determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the directors are responsible for assessing the company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the directors either intend to liquidate the company or to cease operations, or have no realistic alternative but to do so.

Auditors' responsibilities for the audit of the financial statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditors' report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud. The extent to which our procedures are capable of detecting irregularities, including fraud, is detailed below.

Based on our understanding of the company and industry, we identified that the principal risks of non-compliance with laws and regulations related to the Companies Act 2006 and UK tax regulations, and we considered the extent to which non-compliance might have a material effect on the financial statements. We evaluated management's incentives and

opportunities for fraudulent manipulation of the financial statements (including the risk of override of controls), and determined that the principal risks were related to posting inappropriate journal entries to manipulate financial performance, and management bias in accounting estimates. Audit procedures performed by the engagement team included:

- Discussions with management and those charged with governance including consideration of known or suspected instances of non-compliance with laws and regulations through fraud or error;
- Review of meeting minutes of those charged with governance;
- Review of legal expense accounts, assessing whether the nature of costs were indicative of non-compliance with laws and regulations;
- Testing journal entries meeting specific risk criteria, testing accounting estimates for indication of management bias, and evaluating the business rationale of any significant transactions outside the normal course of business; and
- Designing audit procedures to incorporate unpredictability around the nature, timing or extent of our testing.

There are inherent limitations in the audit procedures described above. We are less likely to become aware of instances of non-compliance with laws and regulations that are not closely related to events and transactions reflected in the financial statements. Also, the risk of not detecting a material misstatement due to fraud is higher than the risk of not detecting one resulting from error, as fraud may involve deliberate concealment by, for example, forgery or intentional misrepresentations, or through collusion.

A further description of our responsibilities for the audit of the financial statements is located on the FRC's website at: www.frc.org.uk/auditorsresponsibilities. This description forms part of our auditors' report.

Use of this report

This report, including the opinions, has been prepared for and only for the company's members as a body in accordance with Chapter 3 of Part 16 of the Companies Act 2006 and for no other purpose. We do not, in giving these opinions, accept or assume responsibility for any other purpose or to any other person to whom this report is shown or into whose hands it may come save where expressly agreed by our prior consent in writing.

Other required reporting

Companies Act 2006 exception reporting

Under the Companies Act 2006 we are required to report to you if, in our opinion:

- we have not obtained all the information and explanations we require for our audit; or
- adequate accounting records have not been kept by the company, or returns adequate for our audit have not been received from branches not visited by us; or
- certain disclosures of directors' remuneration specified by law are not made; or
- the financial statements are not in agreement with the accounting records and returns.

We have no exceptions to report arising from this responsibility.

Kirsty Luke

Kirsty Luke (Senior Statutory Auditor)
for and on behalf of PricewaterhouseCoopers LLP
Chartered Accountants and Statutory Auditors
Manchester
26 July 2023

AVOCADO RESEARCH CHEMICALS LIMITED
PROFIT AND LOSS ACCOUNT
FOR THE YEAR ENDED 31 DECEMBER 2022

	Note	2022 £'000	2021 £'000
Turnover	5	25,791	24,288
Cost of sales		(20,921)	(20,487)
Gross profit		4,870	3,801
Distribution costs		(2,123)	(1,909)
Administrative expenses		(2,121)	(2,033)
Exceptional items	6	—	(25)
Other operating (Losses)		(539)	—
Operating Profit/ (loss)	6	87	(141)
Profit before interest and taxation		87	(141)
Net interest (expense)/income	8	(42)	(3)
Profit before taxation		45	(144)
Tax on (Loss)/ Profit	9	(169)	130
(Loss)/ Profit for the financial year		(124)	(14)

Results in the current and previous financial year are from continuing operations only.


No separate statement of comprehensive income has been presented because the company has no other comprehensive income other than profit for the financial year.

AVOCADO RESEARCH CHEMICALS LIMITED
BALANCE SHEET
AS AT 31 DECEMBER 2022

	Note	2022 £'000	2021 £'000
Fixed assets			
Intangible assets	10	287	271
Tangible assets	11	5,079	5,366
		5,366	5,637
Current assets			
Inventories	12	11,354	9,502
Debtors	13	7,592	8,519
Cash at bank and in hand		1,407	305
		20,353	18,326
Creditors: amounts falling due within one year	14	(7,979)	(6,306)
Net current assets		12,374	12,020
Total assets less current liabilities		17,740	17,657
Net assets		17,740	17,657
Capital and reserves			
Called up share capital	18	2,302	2,302
Share premium account		1	1
Retained earnings		15,437	15,354
Total equity		17,740	17,657

The notes on pages 15 to 34 are an integral part of these financial statements.

The financial statements on pages 12 to 34 were authorised for issue by the board of directors on 26 July 2023 and were signed on its behalf

DocuSigned by:

 2017 19E0E436A8D

E Cameron

Director

Avocado Research Chemicals Limited

Company registration number: 02682211

AVOCADO RESEARCH CHEMICALS LIMITED
STATEMENT OF CHANGES IN EQUITY
FOR THE YEAR ENDED 31 DECEMBER 2022

	Note	Called-up share capital	Share premium account	Retained earnings ¹	Total equity
		£'000	£'000	£'000	£'000
Balance as at 1 January 2021		23,015	1	2,140	25,156
Profit for the financial year		—	—	14	14
Total comprehensive income for the year		—	—	14	14
Current Year Corporation tax		—	—	130	130
Charge from parent for equity-settled share-based payments	6	—	—	15	15
Reduction in Issued Share Capital		(20,713)	—	20,713	—
Dividends	18	—	—	(7,500)	(7,500)
Total transactions with owners, recognised directly in equity		(20,713)	—	13,228	7,355
Balance as at 31 December 2021		2,302	1	15,354	17,657
Balance as at 1 January 2022		2,302	1	15,354	17,657
Profit for the financial year		—	—	45	45
Current Year Corporation tax		—	—	(169)	(169)
Charge from parent for equity-settled share-based payments	6	—	—	207	207
Total transactions with owners, recognised directly in equity		—	—	207	207
Balance as at 31 December 2022		2,302	1	15,437	17,740

¹ Retained earnings represents accumulated comprehensive income for the current financial year and prior financial year plus share-based payments adjustments and related tax credits, charges from the parent company for share-based payments less dividends paid.

AVOCADO RESEARCH CHEMICALS LIMITED

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2022

1. General Information

Avocado Research Chemicals Limited ('the company') principal activity is the manufacture and retail of research chemicals. The company has one manufacturing plant in the UK and sells primarily to UK, the rest of Europe & Asia Pacific. The company is a private company limited by shares and is incorporated in England and Wales, United Kingdom. The address of its registered office is 3rd Floor, 1 Ashley Road, Altrincham, Cheshire, WA14 2DT.

2. Statement of compliance

The individual financial statements of Avocado Research Chemicals Limited have been prepared in compliance with United Kingdom Accounting Standards, including Financial Reporting Standard 102, "The Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland" ("FRS 102") and the Companies Act 2006.

3. Summary of significant accounting policies

The principal accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.

Basis of preparation

These financial statements have been prepared on a going concern basis, under the historical cost convention.

The preparation of financial statements in conformity with FRS 102 requires the use of certain critical accounting estimates. It also requires management to exercise its judgement in the process of applying the company's accounting policies. The areas involving a higher degree of judgement or complexity, or areas where assumptions and estimates are significant to the financial statements are disclosed in note 4.

Going Concern

The company meets its day-to-day working capital requirements through its bank facilities. The current economic conditions continue to create uncertainty over (a) the level of demand for the company's products; and (b) the availability of bank finance for the foreseeable future.

The banking financing arrangements of the Company includes cash held by group entities under cash sweep arrangements (as reported within debtors as amounts owed to group undertakings). Amounts held within the in-house bank are repayable on demand.

The company's forecasts and predictions, taking account of reasonably possible changes in trading performance, show that the directors have a reasonable expectation that the company has access to adequate resources to continue in operational existence for the foreseeable future. The company therefore continues to adopt the going concern basis in preparing its financial statements.

As a participant in the cash sweep arrangement, a letter of support has been obtained from Thermo Fisher Scientific Inc., who have confirmed they will continue to support the company and provide any further intercompany financing, if required, for a period of 12 months from the date of approval of the financial statements.

After making enquiries, the directors have a reasonable expectation that the company has adequate resources to continue in operational existence for a period of at least 12 months for the date of approving these financial statements. The company therefore continues to adopt the going concern basis in preparing its financial statements.

AVOCADO RESEARCH CHEMICALS LIMITED

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2022

3. Summary of significant accounting policies (continued)

Exemptions for qualifying entities under FRS 102

FRS 102 allows a qualifying entity certain disclosure exemptions.

Cash flow statement and related party disclosures

The company is included in the consolidated financial statements of Thermo Fisher Scientific Inc. which are publicly available. Consequently, as the company is a 100% owned subsidiary, the company has taken advantage of the exemption, under FRS 102 paragraph 1.12(b), from preparing a statement of cash flows, on the basis that it is a qualifying entity and its ultimate parent company, Thermo Fisher Scientific Inc. includes the company's cash flows in its own consolidated financial statements. The company is also exempt under the terms of FRS 102 paragraph 33.1 from disclosing related party transactions with entities that are part of the Thermo Fisher Scientific Inc. group (see note 20).

Share-based payments

The company has taken advantage of the exemption under FRS 102 para 26.16 where the company is a member of a group share-based payment arrangement and where the company's expense is based on a reasonable allocation and disclosed in full in the consolidated group financial statements.

Foreign currency

(i) Functional and presentation currency

The company's functional and presentation currency is the pound sterling.

(ii) Transactions and balances

Transactions in foreign currencies are translated into sterling at the exchange rate ruling at the date of the transaction.

Monetary assets and liabilities denominated in foreign currencies are translated into sterling at the rates of exchange ruling at the balance sheet date. Any gain or loss arising from a change in exchange rates subsequent to the date of the transactions is included as an exchange gain or loss in the Profit and Loss account except when deferred in other comprehensive income as qualifying cash flow hedges.

Non-monetary items measured at historical costs are translated using the exchange rate at the date of the transaction and non-monetary items measured at fair value are measured using the exchange rate when fair value was determined.

Foreign exchange gains and losses that relate to borrowings and cash and cash equivalents are presented in the Profit and Loss account within 'Finance (expense) / income'. All other foreign exchange gains and losses are presented in the profit and loss account within 'Other operating (losses) / gains'.

Revenue recognition

Revenue is measured at the fair value of the consideration received or receivable and represents the amount received for goods supplied, net of returns, discounts and rebates allowed by the company and value added taxes.

AVOCADO RESEARCH CHEMICALS LIMITED

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2022

3. Summary of significant accounting policies (continued)

Revenue recognition (continued)

The company bases its estimate of returns on historical results, taking into consideration the type of customer, the type of transaction and the specifics of each arrangement.

Where the consideration receivable in cash or cash equivalents is deferred, and the arrangement constitutes a financing transaction, the fair value of the consideration is measured as the present value of all future receipts using the imputed rate of interest.

The company recognises revenue from the sale of goods when all the following conditions are satisfied:

- (a) the entity has transferred to the buyer the significant risks and rewards of ownership of the goods;
- (b) the entity retains neither continuing managerial involvement to the degree usually associated with ownership nor effective control over the goods sold;
- (c) the amount of revenue can be measured reliably;
- (d) it is probable that the economic benefits associated with the transaction will flow to the entity; and
- (e) the costs incurred or to be incurred in respect of the transaction can be measured reliably.

Other operating income

Other operating income recognises adjustments made for the Research and Development expenditure credit.

Interest income

Interest income is recognised using the effective interest rate method.

Employee benefits

The company provides a range of benefits to employees, including annual bonus arrangements, paid holiday arrangements and defined contribution pension plans.

(i) Short term benefits

Short term benefits, including holiday pay and other similar non-monetary benefits, are recognised as an expense in the period in which the service is received.

(ii) Defined contribution pension plans

The company operates a defined contribution pension scheme. The assets of the scheme are held separately from those of the company in an independently administered fund.

For defined contribution schemes the amount charged to the profit and loss account in respect of pension costs is the contribution payable in the year. Differences between contributions payable and actually paid are shown as either accruals or prepayments in the balance sheet.

Annual bonus plan

The company operates an annual bonus plan for employees. An expense is recognised in the profit and loss account when the company has a legal or constructive obligation to make payments under the plan as a result of past events and a reliable estimate of the obligation can be made.

AVOCADO RESEARCH CHEMICALS LIMITED

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2022

3. Summary of significant accounting policies (continued)

Share-based payments

Where the company participates in a share-based payment arrangement established by a group company the company takes advantage of the alternative treatment allowed under Section 26 of FRS 102. The company recognises the share-based payment expense based on an allocation of its share of the group's total expense, calculated in proportion to the number of participating employees. The corresponding credit is recognised in retained earnings as a component of equity. Where the company is charged for the cost of share-based payments arrangements the amounts are treated as a reduction to retained earnings.

These financial statements include no disclosure in regards to share-based payments because the amounts are not material.

Taxation

Taxation expense for the period comprises current and deferred tax recognised in the reporting period. Tax is recognised in the profit and loss account, except to the extent that it relates to items recognised in other comprehensive income or directly in equity. In this case tax is also recognised in other comprehensive income or directly in equity respectively.

Current or deferred taxation assets and liabilities are not discounted.

(i) Current tax

Current tax is the amount of income tax payable in respect of the taxable profit for the year or prior years. Tax is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the period end. Management periodically evaluates positions taken in tax returns with respect to situations in which applicable tax regulation is subject to interpretation. It establishes provisions where appropriate on the basis of amounts expected to be paid to the tax authorities.

(ii) Deferred tax

Deferred tax arises from timing differences that are differences between taxable profits and total comprehensive income as stated in the financial statements. These timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements.

Deferred tax is recognised on all timing differences at the reporting date except for certain exceptions. Unrelieved tax losses and other deferred tax assets are only recognised when it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the period end and that are expected to apply to the reversal of the timing difference.

Intangible assets

Software Costs

Software costs, are stated at cost and are amortised over their useful life of between 2 and 8 years. Amortisation is charged to "Administrative expenses" in the Profit and Loss account.

AVOCADO RESEARCH CHEMICALS LIMITED

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2022

3.1 Summary of significant accounting policies (continued)

Tangible assets

Tangible fixed assets are stated at historic purchase cost, net of accumulated depreciation and any provision for impairment. Cost includes the original purchase price of the asset and costs attributable to bringing the asset into its working condition for its intended use.

Land and buildings

Land and buildings are stated at cost (or deemed cost for land and buildings held at valuation at the date of transition to FRS 102) less accumulated depreciation and accumulated impairment losses.

The difference between depreciation based on the deemed cost charged in the profit and loss account and the asset's original cost is transferred from revaluation reserve to retained earnings.

Plant and machinery and fixtures, fittings, tools and computer equipment

Plant and machinery and fixtures, fittings, tools and equipment are stated at cost less accumulated depreciation and accumulated impairment losses.

Depreciation and residual values

Freehold land is not depreciated

The fixed assets have been depreciated on a straight line basis at rates calculated to reduce the net book value of each asset to its estimated residual value by the end of its expected useful economic life in the company's business, and the rates are as follows:

Freehold land and buildings and lease hold improvements	- 40 years
Plant and machinery	- 7 to 10 years
Fixtures, fittings and computer equipment	- 3 to 10 years

The assets' residual values and useful lives are reviewed, and adjusted, if appropriate, at the end of each reporting year. The effect of any change is accounted for prospectively.

Subsequent additions and major components

Subsequent costs, including major inspections, are included in the assets carrying amount or recognised as a separate asset, as appropriate, only when it is probable that economic benefits associated with the item will flow to the company and the cost can be measured reliably.

The carrying amount of any replaced component is derecognised. Major components are treated as a separate asset where they have significantly different patterns of consumption of economic benefits and are depreciated separately over its useful life.

Repairs, maintenance and minor inspection costs are expensed as incurred.

Assets in the course of construction

Assets under the course of construction are depreciated when they first come into use.

Derecognition

Tangible assets are derecognised on disposal or when no future economic benefits are expected. On disposal, the difference between the net disposal proceeds and the carrying amount is recognised in profit or loss and included in 'Other operating (losses)/gains'.

AVOCADO RESEARCH CHEMICALS LIMITED

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2022

3. Summary of significant accounting policies (continued)

Finance leased assets

Leases of assets that transfer substantially all the risks and rewards incidental to ownership are classified as finance leases.

Finance leases are capitalised at commencement of the lease as assets at the fair value of the leased asset or, if lower, the present value of the minimum lease payments calculated using the interest rate implicit in the lease. Where the implicit rate cannot be determined the company's incremental borrowing rate is used. Incremental direct costs, incurred in negotiating and arranging the lease, are included in the cost of the asset.

Assets are depreciated over the shorter of the lease term and the estimated useful life of the asset. Assets are assessed for impairment at each reporting date.

The capital element of lease obligations is recorded as a liability on inception of the arrangement. Lease payments are apportioned between capital repayment and finance charge, using the effective interest rate method, to produce a constant rate of charge on the balance of the capital repayments outstanding.

Operating leased assets

Leases that do not transfer all the risks and rewards of ownership are classified as operating leases. Payments under operating leases are charged to the profit and loss account on a straight-line basis over the period of the lease.

Inventories

Inventories are stated at the lower of cost and estimated selling price less costs to complete and sell. Inventories are recognised as an expense in the period in which the related revenue is recognised.

Cost is determined on the weighted average costs method. Cost includes the purchase price, including taxes and duties and transport and handling directly attributable to bringing the inventory to its present location and condition. The cost of manufactured finished goods and work in progress includes design costs, raw materials, direct labour and other direct costs and related production overheads (based on normal operating capacity).

At the end of each reporting period inventories are assessed for impairment. If an item of inventory is impaired, the identified inventory is reduced to its selling price less costs to complete and sell and an impairment charge is recognised in the profit and loss account. Where a reversal of the impairment is recognised the impairment charge is reversed, up to the original impairment loss, and is recognised as a credit in the profit and loss account.

Cash and cash equivalents

Cash and cash equivalents includes cash in hand and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities.

AVOCADO RESEARCH CHEMICALS LIMITED

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2022

3. Summary of significant accounting policies (continued)

Provisions and contingencies

Provisions

Provisions are recognised when the company has a present legal or constructive obligation as a result of past events; it is probable that an outflow of resources will be required to settle the obligation; and the amount of the obligation can be estimated reliably.

Where there are a number of similar obligations, the likelihood that an outflow will be required in settlement is determined by considering the class of obligations as a whole.

A provision is recognised even if the likelihood of an outflow with respect to any one item included in the same class of obligations may be small.

In particular:

(i) Restructuring provisions are recognised when the company has a detailed, formal plan for the restructuring and has raised a valid expectation in those affected by either starting to implement the plan or announcing its main features to those affected and therefore has a legal or constructive obligation to carry out the restructuring; and

(ii) Provision is not made for future operating losses.

(iii) Provisions are measured at the present value of the expenditures expected to be required to settle the obligation using a pre-tax rate that reflects current market assessments of the time value of money and the risks specific to the obligation. The increase in the provision due to passage of time is recognised as a finance cost.

Contingencies

Contingent liabilities are not recognised. Contingent liabilities arise as a result of past events when (i) it is not probable that there will be an outflow of resources or that the amount cannot be reliably measured at the reporting date or (ii) when the existence will be confirmed by the occurrence or non-occurrence of uncertain future events not wholly within the company's control. Contingent liabilities are disclosed in the financial statements unless the probability of an outflow of resources is remote. Contingent assets are not recognised. Contingent assets are disclosed in the financial statements when an inflow of economic benefits is probable.

Financial instruments

The company has chosen to adopt the Sections 11 and 12 of FRS 102 in respect of financial instruments.

Financial assets

Basic financial assets, including trade and other receivables, cash and bank balances and investments in commercial paper, are initially recognised at transaction price, unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest.

Such assets are subsequently carried at amortised cost using the effective interest method.

At the end of each reporting year financial assets measured at amortised cost are assessed for objective evidence of impairment. If an asset is impaired the impairment loss is the difference between the carrying amount and the present value of the estimated cash flows discounted at the asset's original effective interest rate. The impairment loss is recognised in profit or loss.

AVOCADO RESEARCH CHEMICALS LIMITED

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2022

3. Summary of significant accounting policies (continued)

Financial instruments (continued)

If there is decrease in the impairment loss arising from an event occurring after the impairment was recognised the impairment is reversed. The reversal is such that the current carrying amount does not exceed what the carrying amount would have been had the impairment not previously been recognised. The impairment reversal is recognised in profit or loss.

Other financial assets, including investments in equity instruments which are not subsidiaries, associates or joint ventures, are initially measured at fair value, which is normally the transaction price.

Such assets are subsequently carried at fair value and the changes in fair value are recognised in profit or loss, except that investments in equity instruments that are not publicly traded and whose fair values cannot be measured reliably are measured at cost less impairment.

Financial assets are derecognised when (a) the contractual rights to the cash flows from the asset expire or are settled, or (b) substantially all the risks and rewards of the ownership of the asset are transferred to another party or (c) control of the asset has been transferred to another party who has the practical ability to unilaterally sell the asset to an unrelated third party without imposing additional restrictions.

Financial liabilities

Basic financial liabilities, including trade and other payables, bank loans, loans from fellow group companies and preference shares that are classified as debt, are initially recognised at transaction price, unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future receipts discounted at a market rate of interest.

Debt instruments are subsequently carried at amortised cost, using the effective interest rate method.

Fees paid on the establishment of loan facilities are recognised as transaction costs of the loan to the extent that it is probable that some or all of the facility will be drawn down. In this case, the fee is deferred until the draw-down occurs. To the extent there is no evidence that it is probable that some or all of the facility will be drawn down, the fee is capitalised as a pre-payment for liquidity services and amortised over the period of the facility to which it relates.

Preference shares, which result in fixed returns to the holder or are mandatorily redeemable on a specific date, are classified as liabilities. The dividends on these preference shares are recognised in the profit and loss account as interest expense.

Trade payables are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Accounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Trade payables are recognised initially at transaction price and subsequently measured at amortised cost using the effective interest method.

Derivatives, including interest rate swaps and forward foreign exchange contracts, are not basic financial instruments.

The company does not currently apply hedge accounting for interest rate and foreign exchange derivatives.

Financial liabilities are derecognised when the liability is extinguished, that is when the contractual obligation is discharged, cancelled or expires.

AVOCADO RESEARCH CHEMICALS LIMITED

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2022

3. Summary of significant accounting policies (continued)

Financial instruments (continued)

Offsetting

Financial assets and liabilities are offset and the net amounts presented in the financial statements when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

Share capital

Ordinary shares are classified as equity. Incremental costs directly attributable to the issue of new ordinary shares or options are shown in equity as a deduction, net of tax, from the proceeds.

Distributions to equity holders

Dividends and other distributions to company's shareholders are recognised as a liability in the financial statements in the period in which the dividends and other distributions are approved by the company's shareholders. These amounts are recognised in the statement of changes in equity.

Related party transactions

The company discloses transactions with related parties which are not wholly owned with the same group. It does not disclose transactions with members of the same group that are wholly owned.

Exceptional Items

The company classifies certain one-off charges or credits that have a material impact on the group's financial results as 'exceptional items'. These are disclosed separately to provide further understanding of the financial performance of the company.

4. Critical accounting judgements and estimation uncertainty

Estimates and judgements are continually evaluated and are based on historical experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances.

(a) Critical accounting estimates and assumptions

The company makes estimates and assumptions concerning the future. The resulting accounting estimates will, by definition, seldom equal the related actual results. The estimates and assumptions that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities within the next financial year are addressed below.

(i) Useful economic lives of tangible assets

The annual depreciation charge for tangible assets is sensitive to changes in the estimated useful economic lives and residual values of the assets. The useful economic lives and residual values are re-assessed annually. They are amended when necessary to reflect current estimates, based on technological advancement, future investments, economic utilisation and the physical condition of the assets. See note 11 for the carrying amount of the property plant and equipment, and note 3 for the useful economic lives for each class of assets.

AVOCADO RESEARCH CHEMICALS LIMITED

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2022

4. Critical accounting judgements and estimation uncertainty (continued)

(a) Critical accounting estimates and assumptions (continued)

(ii) Inventory provisioning

The company manufactures and sells research chemicals. As a result it is necessary to consider the recoverability of the cost of inventory and the associated provisioning required. When calculating the inventory provision, management considers the nature and condition of the inventory, as well as applying assumptions around anticipated sale ability of finished goods and future usage of raw materials. See note 12 for the net carrying amount of the inventory and associated provision.

(iii) Impairment of debtors

The company makes an estimate of the recoverable value of trade and other debtors. When assessing impairment of trade and other debtors, management considers factors including the current credit rating of the debtor, the ageing profile of debtors and historical experience. See note 13 for the net carrying amount of the debtors and associated impairment provision.

5. Turnover

Turnover by geography	2022 £'000	2021 £'000
United Kingdom	9,404	9,322
Rest of Europe	4,337	5,235
Rest of World	12,050	9,731
	25,791	24,288
Turnover by nature	2022 £'000	2021 £'000
Sales of goods	25,791	24,288
	25,791	24,288

AVOCADO RESEARCH CHEMICALS LIMITED**NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2022****6. Operating Loss**

The operating loss is stated after charging/(crediting):

	Note	2022 £'000	2021 £'000
Wages and salaries		5,228	4,865
Social security costs		485	531
Other pension costs	15	286	261
Share-based payments		207	15
Staff costs		6,205	5,672
Reorganisation expense		0	25
Impairment of trade receivables			13
Amortisation of intangible assets (included in 'administrative expenses')	10	57	73
Inventory recognised as an expense		12,668	11,884
Reversal of impairment of inventory (included in 'cost of sales')		(14)	(31)
Operating lease charges			
- Plant and Machinery		46	56
Depreciation of tangible fixed assets	11		
- Owned assets		659	640
Foreign exchange (gain)/loss		(15)	51
Audit fees payable to the company's auditors for statutory audit		106	49
Research and development expenditure		180	177

Exceptional items	2022 £'000	2021 £'000
During the year the company had the following exceptional items:		
Cost of reorganisation	—	25

Cost of fundamental reorganisation relate mainly to redundancy payments incurred in connection with reorganisation of the business.

There were no non-audit fees payable to the company's auditors in the financial year (2021: £nil).

AVOCADO RESEARCH CHEMICALS LIMITED**NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2022****7. Employees and directors**

Average monthly numbers of persons employed (including directors) by the company during the year was:

By activity	2022	2021
	Number	Number
Sales and marketing	13	13
Manufacturing	101	95
Research and development	4	4
Administration	22	13
	140	125

Directors

Directors' emoluments represent an allocation of their services to this company.

	2022	2021
	£'000	£'000
Aggregate emoluments	257	269
Aggregate amounts (including shares) receivable under long-term incentive schemes	37	19
Company contributions to defined contribution pension scheme	12	11
	306	299

Retirement benefits accrued to no directors (2021: no directors) under a defined benefit scheme.
Retirement benefits accrued to 3 (2021: 3) directors under a money purchase pension scheme.

During the year 2 directors (2021: 3 directors) exercised options over shares of Thermo Fisher Scientific Inc.

In 2022 3 (2021: 4) directors were entitled to shares under a long-term incentive scheme.

Highest paid director	2022	2021
	£'000	£'000
Aggregate emoluments	257	266
Aggregate amounts (including shares) receivable under long-term incentive schemes	37	19
Company contributions to defined contribution pension scheme	12	11
	306	296

The highest paid director exercised share options over shares in Thermo Fisher Scientific Inc. during 2021.

AVOCADO RESEARCH CHEMICALS LIMITED**NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2022****8. Net interest Expense**

Interest Payable and similar charges	2022 £'000	2021 £'000
Interest Payable from group undertakings	(42)	(3)
Total interest payable and similar charges	(42)	(3)
Net interest Expense	(42)	(3)

9. Tax on (loss) / profit

Tax expense included in profit and loss

	Note	2022 £'000	2021 £'000
Current tax			
UK corporation tax on profits for the year		—	—
Adjustment in respect of previous periods		24	14
Total current tax		24	14
Deferred tax			
Origination and reversal of timing differences		31	37
Impact of changes in tax rates		10	(181)
Adjustments in respect of previous years		104	—
Total deferred tax	16	145	(144)
Tax on profit		169	(130)

Reconciliation of tax charge/credit:

The tax assessed for the year is lower (2021: lower than) than the standard rate of corporation tax in the UK 19.00% (2021: 19.00%): The differences are outlined below:

AVOCADO RESEARCH CHEMICALS LIMITED**NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2022****9. Tax on (loss) / profit (continued)**

	2022	2021
	£'000	£'000
Profit before taxation	45	(144)
Profit before taxation multiplied by the standard rate of corporation tax in the UK 19.00% (2021: 19.00%)	9	(27)
Effects of:		
Expenses not deductible for tax purposes	215	27
Deferred tax on share options	—	—
Group relief claimed	(112)	19
Fixed asset differences	—	—
Tax relief for employee share acquisition	(57)	18
Remeasurement of deferred tax for changes in tax rates	10	(181)
Adjustments in respect of previous periods	104	14
Total tax deduction/(credit) for the year	169	(130)

Factors that may affect future tax charges:

The UK headline corporation tax rate for the period was 19% (2021: 19.00%). In the Spring Budget on 3 March 2021 it was announced that the UK Corporation Tax rate would increase to 25% with effect from 1 April 2023 and was substantively enacted on 24 May 2021. Therefore at the balance sheet date deferred tax is measured at the rate that will be enacted or substantively enacted on the date when the underlying temporary differences are expected to unwind.

AVOCADO RESEARCH CHEMICALS LIMITED**NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2022****10. Intangible assets**

	Software £'000	Total £'000
Cost		
At 1 January 2022	2,314	2,314
Additions	54	54
Transfers	22	22
Disposals	(3)	(3)
At 31 December 2022	2,387	2,387
Accumulated amortisation		
At 1 January 2022	2,044	2,044
Charge for the year	57	57
At 31 December 2022	2,100	2,100
Net book value		
At 31 December 2022	287	287
At 31 December 2021	271	271

AVOCADO RESEARCH CHEMICALS LIMITED**NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2022****11. Tangible assets**

	Freehold land and buildings and leasehold improvements £'000	Plant and machinery £'000	Fixtures, fittings and computer equipment £'000	Total £'000
Cost				
At 1 January 2022	6,879	4,354	3,791	15,024
Additions	28	31	340	399
Transfers	(9)	(128)	115	(22)
Disposals			(4)	(4)
At 31 December 2022	6,899	4,257	4,241	15,397
Accumulated depreciation				
At 1 January 2022	3,616	3,646	2,397	9,659
Charge for the year	243	110	306	659
At 31 December 2022	3,860	3,756	2,703	10,318
Net book value				
At 31 December 2022	3,040	487	1,559	5,079
At 31 December 2021	3,264	708	1,394	5,365

12. Inventories

	2022 £'000	2021 £'000
Raw materials and consumables	668	1,192
Work in progress	77	65
Finished goods and goods for resale	10,609	8,245
	11,354	9,502

There is no significant difference between the replacement cost of work in progress and finished goods and goods for resale and their carrying amounts.

Inventories are stated after provisions for impairment of £5,403,000 (2021: £5,986,000).

AVOCADO RESEARCH CHEMICALS LIMITED**NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2022****13. Debtors: amounts falling due within one year**

	2022	2021
	£'000	£'000
Trade debtors	2,287	2,789
Amounts owed by group undertakings	4,373	4,835
Other debtors	47	19
Deferred tax asset	610	755
Corporation tax recoverable	3	3
Prepayments and accrued income	272	118
	7,592	8,519

Trade debtors are stated after provision for impairment of £162,000 (2021: £30,000).

Amounts owed by group undertakings

Cash held by group entities under the cash sweep arrangement is included under creditor as amounts owed to group undertakings, this amounted to £1,148,000 (2021: £1,280,000) at the year end. The management company, Life Technologies Finance Limited, shall effect quarterly the calculation for distributions of debit interest or credit interest at rate of LIBOR 0.5% among the parties and settle this accordingly on the in-house bank accounts of the participant with the management company. It is repayable on demand. The remainder of the amounts owed by group undertakings are intercompany trade receivables, these are interest free and repayable on demand.

14. Creditors: amounts falling due within one year

	2022	2021
	£'000	£'000
Trade creditors	(2,021)	(1,720)
Amounts owed to group undertakings	(4,791)	(3,202)
Other creditors	(111)	(117)
Corporation tax	0	(14)
Other taxation and social security	(87)	(108)
Accruals and deferred income	(969)	(1,145)
	(7,979)	(6,306)

Amounts owed to group undertakings

Amounts owed to group undertakings includes cash sweep arrangement and intercompany trade payables these are interest free and repayable on demand.

15. Post-employment benefits

The company operates a defined contribution scheme. The pension cost charge for the year represents contributions payable by the company to the fund and amounted to £286,000 (2021: £261,000). The liability / prepayment at the year end for the contributions payable to the defined contribution scheme is £51,000 (2021: £nil).

AVOCADO RESEARCH CHEMICALS LIMITED**NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2022****16. Deferred tax asset**

	2022 £'000	2021 £'000
Accelerated capital allowances	506	720
Other timing differences	104	35
Deferred tax asset	610	755

	Deferred tax asset £'000
At 1 January 2022	755
Charge to profit and loss account	(41)
Adjustment in respect of previous periods	(104)
At 31 December 2022	610

There are no unused tax losses or unused tax credits.

The UK headline corporation tax rate for the period was 19% (2021: 19.00%). In the Spring Budget on 3 March 2021 it was announced that the UK Corporation Tax rate would increase to 25% with effect from 1 April 2023 and was substantively enacted on 24 May 2021. Therefore at the balance sheet date deferred tax is measured at the rate that will be enacted or substantively enacted on the date when the underlying temporary differences are expected to unwind.

17. Financial Instruments

The company has the following financial instruments:

	Note	2022 £'000	2021 £'000
Financial assets that are debt instruments measured at amortised cost			
– Trade debtors		2,287	2,789
– Amounts owed by group undertakings	13	4,373	4,835
– Other receivables		319	137
		6,979	7,761
Financial liabilities measured at amortised cost			
– Trade creditors		2,021	1,720
– Amounts owed to group undertakings	14	4,791	3,202
– Other creditors		1,167	1,370
		7,979	6,292

AVOCADO RESEARCH CHEMICALS LIMITED**NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2022****17. Financial Instruments (continued)****Derivative financial instruments**

The company has no forward foreign currency contracts to mitigate the exchange rate risk for certain foreign currency receivables.

The company has no interest rate derivative financial instruments (2021: none).

18. Called up share capital

	2022	2021
	£	£
Allotted and fully paid		
23,015,297 (2021: 23,015,297)	2,301,530	2,301,530

	2022	2021
	£'000	£'000
Dividends		
Total dividends paid	—	7,500

19. Capital and other commitments

The company had the following minimum lease payments under non-cancellable operating leases for each of the following periods:

	2022	2021
	£'000	£'000
Plant and machinery and vehicles		
Within one year	37	39
Within two to five years	46	98
	83	137

The company has no other off-balance sheet arrangements.

20. Related party transactions

See note 7 for disclosure of the directors' remuneration and key management compensation.

The company is exempt from disclosing other related party transactions as they are with other companies that are wholly owned within the Group.

AVOCADO RESEARCH CHEMICALS LIMITED

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2022

21. Controlling parties

The immediate parent undertaking is Thermo Fisher (Heysham) Limited whose registered office is 3rd Floor, 1 Ashley Road, Altrincham, Cheshire WA14 2DT.

The ultimate parent undertaking and controlling party is Thermo Fisher Scientific Inc. which is the largest and smallest group to consolidate these financial statements. The company is incorporated in the United States of America and its common stock is listed on the New York Stock Exchange. Copies of the financial statements of the ultimate parent company are publicly available and can be obtained from its headquarters at 168 Third Avenue, Waltham, MA 02451, USA.